cannabidiol/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Increases seizure frequency 50% responder rate
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“The meta‐analysis results for the logistic regression on the 50% responder rate, the key secondary endpoint, also favored CBD vs. placebo regardless of CLB co‐therapy.”
Quoted verbatim from Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.. - Study
- meta-analysis
- Duration
- 3 months
- Dose
- 10 or 20 mg/kg/day oral solution for 14 weeks
- Population
- Patients aged 2 to 55 years with Lennox-Gastaut syndrome or Dravet syndrome in four pooled phase 3 trials; CBD 10 and 20 mg/kg/day versus placebo, both CBD doses combined, analysed in strata with and without concomitant clobazam; antiseizure drugs continued in both arms
Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.2020PMID:32592183Industry fundedPermalink
Keep reading
- Everything the graph holds on cannabidiol
- Every compound studied against Seizure frequency 50% responder rate
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45HMR6AMSMER1HMHN660A5X